Impact of Target‐Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP‐4 Inhibition in Type 2 Diabetic Patients
Authors:
- 1 August 2010
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 50 (8) , 873-885
Abstract
The pharmacokinetics of the novel dipeptidyl‐peptidase 4 (DPP‐4) inhibitor linagliptin is nonlinear. Based on in vitro experiments, concentration‐dependent binding to DPP‐4 is the most likely cause for the nonlinearity. Population pharmacokinetic/pharmacodynamic modeling was performed using linagliptin plasma concentrations and plasma DPP‐4 activities from 2 phase 2a studies. In these studies, type 2 diabetic patients received either 1, 2.5, 5, or 10 mg of linagliptin once daily over 12 days (study 1) or 2.5, 5, or 10 mg of linagliptin once daily over 28 days (study 2). The modeling results supported the hypothesis that linagliptin exhibits target‐mediated drug disposition. The linagliptin plasma concentrations were best described by a 2‐compartment model including concentration‐dependent protein binding in the central and peripheral compartment. The plasma DPP‐4 activity was included in the model in a semi‐mechanistic way by relating it to the model‐calculated plasma DPP‐4 occupancy with linagliptin. The target binding has a major impact on linagliptin pharmacokinetics. Although unbound linagliptin is cleared efficiently (CL/F220 L/h), the concentration‐dependent binding is responsible for the long terminal half‐life (∼120 hours) of linagliptin and its nonlinear pharmacokinetics. The model allowed a comprehensive understanding of the impact of target‐mediated drug disposition and provides a useful tool to support clinical development.Keywords
This publication has 25 references indexed in Scilit:
- Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patientsDiabetes, Obesity and Metabolism, 2009
- Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IVCritical Reviews in Clinical Laboratory Sciences, 2003
- Glucose-Dependent Insulinotropic Polypeptide Is a Growth Factor for (INS-1) Cells by Pleiotropic SignalingMolecular Endocrinology, 2001
- Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serumEuropean Journal of Biochemistry, 1993
- Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrationsThe Journal of Clinical Endocrinology & Metabolism, 1993
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amideDiabetes, 1989
- Expression of dipeptidyl peptidase IV in rat tissues is mainly regulated at the mRNA levelsExperimental Cell Research, 1989
- Immunohistochemical localization of dipeptidyl aminopeptidase IV in rat kidney, liver, and salivary glands.Journal of Histochemistry & Cytochemistry, 1981
- Angiotensin-Converting Enzyme: Vascular Endothelial LocalizationScience, 1976